Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857888 | 0.87 | PSMB5 (0.52) | PYGLPSMB5NPC1RAB9AACKR3 | |
| SCHEMBL2861438 | 0.83 | PSMB5 (0.42) | PYGLPSMB5CNR1CNR2 | |
| SCHEMBL5470915 | 0.82 | DHODH (0.44) | PYGLPSMB5CNR1CNR2NPC1 | |
| SCHEMBL2858587 | 0.79 | PSMB5 (0.51) | PYGLPSMB5POLBACKR3DHODH | |
| SCHEMBL2856032 | 0.79 | HPGD (0.51) | KMT2AACKR3 | |
| SCHEMBL2861620 | 0.77 | CTRB1 (0.51) | NPC1RAB9A | |
| SCHEMBL2853485 | 0.77 | NPC1 (0.51) | KMT2APOLBNPC1RAB9A | |
| SCHEMBL2861403 | 0.77 | L3MBTL1 (0.49) | PYGLPSMB5NPC1RAB9AACKR3 | |
| SCHEMBL2856055 | 0.76 | PTGES (0.45) | — | |
| SCHEMBL5453401 | 0.76 | ACKR3 (0.46) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | PYGL 4182/4885KMT2A 1396/4885PSMB5 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.